GLS4 莫非賽定 Morphothiadin

具體成交價(jià)以合同協(xié)議為準(zhǔn)

公司名稱 MedChemExpress LLC
品牌 MedChemExpress (MCE)
型號(hào) GLS4
產(chǎn)地
廠商性質(zhì) 生產(chǎn)廠家
更新時(shí)間 2019/6/27 8:50:13
訪問(wèn)次數(shù) 752

產(chǎn)品標(biāo)簽

GLS4 morphothiadin

在線交流發(fā)送詢價(jià) 查看電話同類產(chǎn)品

聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息,，謝謝!

索取相關(guān)資料

公司介紹 主營(yíng)產(chǎn)品

MedChemExpress (MCE) 專注于為科學(xué)家提供高品質(zhì)的生物活性小分子化合物,，化合物庫(kù)及各類試劑盒，總部位于美國(guó)新澤西,。
•   MedChemExpress (MCE) 產(chǎn)品作用于 20 多個(gè)熱門信號(hào)通路及研究領(lǐng)域的300多個(gè)細(xì)分靶點(diǎn)，擁有 10000 特異性抑制劑,、激動(dòng)劑,，以及 50 活性化合物篩選庫(kù)；
•   我們堅(jiān)持對(duì)所有產(chǎn)品進(jìn)行嚴(yán)格質(zhì)檢,，確保產(chǎn)品的高品質(zhì)和高純度,；
•   MedChemExpress (MCE) 產(chǎn)品已被數(shù)萬(wàn)名科學(xué)家信賴，并被大量top文獻(xiàn)和*引用,；
•   我們擁有專業(yè)的技術(shù)團(tuán)隊(duì)追蹤前沿科研進(jìn)展,，不斷豐富各個(gè)靶點(diǎn)的特異性產(chǎn)品,，堅(jiān)持做 “您身邊的抑制劑大師”；
•   MedChemExpress (MCE) 與眾多藥企和科研機(jī)構(gòu)保持深度合作,；
•   大量產(chǎn)品有中國(guó)庫(kù)存,，工作日 16:00 前訂單確保當(dāng)日發(fā)貨，次日送達(dá),。
MCE 中國(guó)站：www.MedChemExpress.cn

Hotline: 400-820-3792
Tel: 021-58955995
Email: [email protected]
Tech Support: 021-58950656

MedChemExpress - Inhibitors Agonists

MedChemExpress - Screening Libraries

MedChemExpress - Top Publications Citing Use of MCE

展開(kāi)

抑制劑,，調(diào)節(jié)劑，API,，天然產(chǎn)物,，各種類型化合物庫(kù)

詳細(xì)信息 在線詢價(jià)

供貨周期	現(xiàn)貨	規(guī)格	10 mM * 1 mL；1 mg,；5 mg,；10 mg；25 mg,；50 mg
貨號(hào)	HY-108917	應(yīng)用領(lǐng)域	生物產(chǎn)業(yè)

Morphothiadin

產(chǎn)品活性：Morphothiadin 是野生型和阿德福韋耐藥 HBV 復(fù)制的有效抑制劑,，其 IC₅₀ 值為 12 nM。

研究領(lǐng)域：Anti-infection

作用靶點(diǎn)：HBV

In Vitro: Morphothiadin is a potent inhibitor on the replication of both wild-type and adefovir-resistant HBV with an IC₅₀ of 12 nM. Morphothiadin (GLS4) shows no toxicity up to 25 μM. The cytotoxic dose whereby 50% of cells die (CC₅₀) for primary hepatocytes is 115 μM for Morphothiadin (P<0.001). The CC₉₀ is 190 μM for Morphothiadin (P<0.01) in HepAD38 cells. Morphothiadin strongly inhibits virus accumulation in the supernatant of HepAD38 cells at 25 nM to 100 nM (P<0.02). Results show a concentration-dependent decrease of core protein in cells treated with Morphothiadin.

In Vivo: The area under the concentration-time curve from 0 to 24 h (AUC_0-24) of Morphothiadin (GLS4) is 556 h?ng/mL. After intravenous administration of 10 mg/kg Morphothiadin, the total plasma clearance and apparent volume distribution are 4.2 liters/h/kg and 7.38 liters/kg, respectively. The bioavailability of Morphothiadin is 25.5%. It is found that virus titers have increased 83.5-fold in mice treated with 3.75 mg/kg per day of Morphothiadin, 28.3-fold among mice treated with 7.5 mg/kg per day, but only 3- to 6-fold among mice treated with the higher doses of Morphothiadin. There is generally an inverse relationship between Morphothiadin dose and virus titer, with the greatest rebound seen in mice treated with 3.75 mg/kg per day of Morphothiadin (540-fold) and the smallest rebound in mice treated with 60 mg/kg per day (23-fold) (P<0.001). The Morphothiadin doses of >7.5 mg/kg per day significantly suppresses the virus replication cycle throughout the treatment period, while Morphothiadin doses of >15 mg/kg per day suppresses virus for up to 2 weeks after the end of treatment.